Crizotinib (PF‐02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P‐glycoprotein
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND PURPOSE: Besides targeting the well‐known oncogenic c‐Met, crizotinib is the first oral tyrosine kinase inhibitor inhibiting anaplastic lymphoma kinase (ALK) in clinical trials for the treatment of non‐small cell lung cancer. Here, we assessed the possible reversal of multidrug resistance (MDR) by crizotinib in vitro and in vivo. EXPERIMENTAL APPROACH: 1‐(4,5‐Dimethylthiazol‐2‐yl)‐3,5‐ diphenylformazan was used in vitro and xenografts in nude mice were used in vivo to investigate reversal of MDR by crizotinib. To understand the mechanisms for MDR reversal, the alterations of intracellular doxorubicin or rhodamine 123 accumulation, doxorubicin efflux, ABCB1 expression level, ATPase activity of ABCB1 and crizotinib‐induced c‐Met, Akt and ERK1/2 phosphorylation were examined. KEY RESULTS: Crizotinib significantly enhanced the cytotoxicity of chemotherapeutic agents which are also ABCB1 substrates, in MDR cells with no effect found on sensitive cells in vitro and in vivo. Additionally, crizotinib significantly increased intracellular accumulation of rhodamine 123 and doxorubicin and inhibited the drug efflux in ABCB1‐overexpressing MDR cells. Further studies showed that crizotinib enhanced the ATPase activity of ABCB1 in a concentration‐dependent manner. However, expression of ABCB1 was not affected, and reversal of MDR by crizotinib was not related to the phosphorylation of c‐Met, Akt or ERK1/2. Importantly, crizotinib significantly enhanced the effect of paclitaxel against KBv200 cell xenografts in nude mice. CONCLUSIONS AND IMPLICATIONS: Crizotinib reversed ABCB1‐mediated MDR by inhibiting ABCB1 transport function without affecting ABCB1 expression or blocking the Akt or ERK1/2 pathways. These findings are useful for planning combination chemotherapy of crizotinib with conventional chemotherapeutic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774 · cited 1×
“The emerging paradigm of molecular targeted chemotherapy has attracted much basic science and clinical research on the novel inhibitors specific for oncogenic receptor tyrosine kinases (RTK) in various cancers (Schlessinger, 2000; BlumeJensen and Hunter, 2001).”
BackgroundBlume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 1×
“To date, three generations of MDR inhibitors have been developed, some of which are currently under clinical trials to evaluate their usefulness in circumventing anticancer drug resistance (Dean et al., 2005; Coley, 2010).”
BackgroundGuide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947 · cited 2×
“E-mail: fulw@mail.sysu.edu.cn or hhongb@mail.sysu.edu.cn ---------------------------------------------------------------- Keywords crizotinib; multidrug resistance; ATP-binding cassette transporters; P-glycoprotein; ABCG2; xenograft…”
BackgroundThe human ATP-binding cassette (ABC) transporter superfamily
Dean, M., Hamon, Y., & Chimini, G. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31588-1 · Cited by 1,302
Dai, C.-L., Tiwari, A. K., Wu, C.-P., Su, X.-D., Wang, S.-R., Liu, D.-G., Ashby, C. R., Huang, Y., Robey, R. W., Liang, Y.-J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0499 · Cited by 386 · cited 2×
“Previously, it has been reported that several tyrosine kinase inhibitors including lapatinib (Dai et al., 2008), gefitinib (Kitazaki et al.”
BackgroundSelf-citationEffects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
Costa, D. B., Nguyen, K.-S. H., Cho, B. C., Sequist, L. V., Jackman, D. M., Riely, G. J., Yeap, B. Y., Halmos, B., Kim, J. H., Jänne, P. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1455 · Cited by 171 · cited 1×
“, 2003), erlotinib in NSCLC with mutant and/or amplified epidermal growth factor receptor (Giaccone, 2005; Costa et al., 2008), trastuzumab in breast cancers with amplified/elevated HER-2 (Emens, 2005; Jackisch, 2006) and sunitinib targeting the von Hippel-Lindau (VHL)-dependent VEGF pathway in renal cell carcinoma (R…”
Background
Cited by
Kathawala, R. J., Gupta, P., Ashby, C. R., & Chen, Z.-S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.002 · Cited by 777
To, K. K. W., Poon, D. C., Wei, Y., Wang, F., Lin, G., & Fu, L.-W. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.06.034 · Cited by 49
Self-citationAyoub, N., Al-Shami, K., Alqudah, M. A. Y., & Mhaidat, N. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s148604 · Cited by 38
Zeng, F., Wang, F., Zheng, Z., Chen, Z., Wah To, K. K., Zhang, H., Han, Q., & Fu, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.008 · Cited by 26
Self-citation
Metadata
- Authors
- Zhou, W., Zhang, X., Cheng, C., Wang, F., Wang, X., Liang, Y., To, K. K. W., Zhou, W., Huang, H., & Fu, L.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2012-06-21
- Volume
- 166
- Issue
- 5
- Pages
- 1669-1683
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1599268777
- Cited by
- 101
- References
- 9
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Crizotinib (PF‐02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P‐glycoprotein. https://app.cochat.ai/papers/10.1111/j.1476-5381.2012.01849.x
- The paper
- Zhou, W., Zhang, X., Cheng, C., Wang, F., Wang, X., Liang, Y., To, K. K. W., Zhou, W., Huang, H., & Fu, L. (2012). Crizotinib (PF‐02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P‐glycoprotein. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2012.01849.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.